English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Bispecific antibodies play an important role in immunotherapy. They have received intense interest from pharmaceutical enterprises. The first antibody drug,  OKT 3 (muromonab‐ CD 3), showed great performance in clinical treatment. We have successfully developed a single‐chain variable fragment (ScFv) combination of anti‐ CD 3 ScFv and anti‐ CD 138 ScFv with the  hIgG 1 Fc ( hIgF c) sequence. The novel bispecific T‐cell engager (Bi TE ) with an additional  hIgF c (Bi TE ‐ hIgF c,  STL 001) can target T cells, natural killer cells, and multiple myeloma cells ( RPMI ‐8226 or U266). In addition, Bi TE ‐ hIgF c ( STL 001) has nanomolar‐level affinity to recombinant human  CD 138 protein and shows more potent antitumor activity against  RPMI ‐8226 cells than that of separate  aCD 3‐ScFv‐ hIgF c and  aCD 138‐ScFv‐ hIgF c, or the isotype  mA b  in vitro  or  in vivo .

Immunotherapy based on bispecific T‐cell engager with hIgG 1 Fc sequence as a new therapeutic strategy in multiple myeloma